What are the effects of fixed-dose combination of candesartan and amlodipine

Czech version

Authors: Jiří Vítovec ¹; Jindřich Špinar ²
Authors‘ workplace: I. interní kardioangiologická klinika LF MU a FN u sv. Anny v Brně ¹; Interní kardiologická klinika LF MU a FN Brno, pracoviště Bohunice ²
Published in: Vnitř Lék 2016; 62(4): 317-321
Category: Reviews

Overview

We are presenting a current view on a fixed-dose combination of amlodipine and candesartan in the treatment of hypertension. Major studies on the individual preparations as well as studies examining their combination are included. This fixed-dose combination expands our possibilities with regard to attaining the blood pressure target values, in particular in patients with risk factors or patients with comorbidities. Finally, the benefit mainly consists in the greater compliance of the patient with a minimum adverse effects.

Key words:
amlodipine – candesartan – fixed-dose combination – hypertension

Sources

1. Rosolová H. Kombinovaná léčba arteriální hypertenze. Vnitř Lék 2013; 59(5): 366–369.

2. Špinar J, Vítovec J, Špinarová L et al. Fixní kombinace v léčbě hypertenze. Vnitř Lék 2012; 58(7–8): 215–222.

3. Filipovský J, Widimský J, Ceral J et al. Diagnostické a léčebné postupy u arteriální hypertenze – verze 2012 Doporučení České společnosti pro hypertenzi. Vnitř Lék 2012; 58(10): 785–801.

4. Nishio K, Kondo T, Kobayashi Y. Efficacy and Tolerability of Candesartan Cilexetil and Amlodipine in Patients with Poorly Controlled Essential Hypertension. Int J Clin Med 2011; 2(2): 64–68.

5. Opie LH. Calcium channel blockers. In: Opie LH, Gersh BJ. Drugs for the Heart. 8th ed. Elsevier Saunders 2013: 64–92. ISBN 978–1455733224.

6. Julius S, Kjeldsen SE, Weber M et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363(9426): 2022–2031.

7. Slíva J. Candesartan v léčbě kardiovaskulárních onemocnění. Farmakoterapie 2012; 8(1): 118–122.

8. Messerli FH, Bangalore S, Ruschitzka F. Angiotensin receptor blockers: baseline therapy in hypertension? Eur Heart J 2009; 30(20): 2427–2430.

9. Papademetriou V, Farsang C, Elmfeldt D et al. Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE). J Am Coll Cardiol 2004; 44(6): 1175–1180.

10. Julius S, Kaciroti N, Egan BM et al. [TROPHY Investigators]. Outcomes based on the Seventh Report of the Joint National Committee on Hypertension definition of hypertension. J Am Soc Hypertens 2008; 2(1): 39–43.

11. Ogihara T, Nakao K, Fukui T et al. Hypertensive Patients With High Cardiovascular Risks Candesartan Antihypertensive Survival Evaluation in Japan Trial. Hypertension 2008; 51(2): 393–398.

12. Takai S, Jin D, Shimosato T et al. Candesartan and amlodipine combination therapy provides powerful vascular protection in stroke-prone spontaneously hypertensive rats. Hypertens Res 2011; 34(2): 245–252.

13. Rakugi H, Ogihara T, Miyata Y et al. Evaluation of the efficacy and tolerability of combination therapy with candesartan cilexetil and amlodipine besilate compared with candesartan cilexetil monotherapy and amlodipine besilate monotherapy in Japanese patients with mild-to-moderate essential hypertension: a multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2012; 34(4): 838–848.

14. Yasuno S, Fujimoto A, Nakagawa Y et al. Fixed-dose combination therapy of candesartan cilexetil and amlodipine besilate for the treatment of hypertension in Japan. Expert Rev Cardiovasc Ther 2012; 10(5): 577–583.

15. Yamaguchi J, Hagiwara N, Ogawa H et al. Effect of amlodipine + candesartan on cardiovascular events in hypertensive patients with coronary artery disease (from The Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease [HIJ-CREATE] Study). Am J Cardiol 2010; 106(6): 819–824.

16. de la Sierra A. Mitigation of calcium channel blocker-related oedema in hypertension by antagonists of the renin-angiotensin system. J Hum Hypertens 2009; 23(8): 503–511.

17. Slíva J. Nová fixní kombinace v klinické praxi v ČR: candesartan + amlodipin. Farmakoterapie 2015; 11(1): 27–29.

18. Vítovec J, Špinar J et al. Farmakoterapie kardiovaskulárních onemocnění. 2. vyd. Grada: Praha 2004. ISBN 80–247–0866–3.